MA41689A - Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine - Google Patents
Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidineInfo
- Publication number
- MA41689A MA41689A MA041689A MA41689A MA41689A MA 41689 A MA41689 A MA 41689A MA 041689 A MA041689 A MA 041689A MA 41689 A MA41689 A MA 41689A MA 41689 A MA41689 A MA 41689A
- Authority
- MA
- Morocco
- Prior art keywords
- prevention
- treatment
- sleep disorders
- dexmedetomidine formulation
- dexmedetomidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462064205P | 2014-10-15 | 2014-10-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA41689A true MA41689A (fr) | 2017-08-22 |
Family
ID=55747372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA041689A MA41689A (fr) | 2014-10-15 | 2015-10-14 | Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine |
Country Status (5)
Country | Link |
---|---|
US (2) | US20170239221A1 (fr) |
EP (1) | EP3206685B1 (fr) |
JP (3) | JP2017534613A (fr) |
MA (1) | MA41689A (fr) |
WO (1) | WO2016061413A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3562486T3 (da) * | 2016-12-31 | 2024-06-10 | Bioxcel Therapeutics Inc | Anvendelse af sublingual dexmedetomidin til behandling af agitation |
CN112888431B (zh) | 2018-06-27 | 2022-06-03 | 比奥克斯塞尔医疗股份有限公司 | 含右美托咪定的膜制剂及其制造方法 |
US20240024288A1 (en) | 2019-07-19 | 2024-01-25 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
CN113827590A (zh) * | 2020-06-08 | 2021-12-24 | 四川普锐特药业有限公司 | 右美托咪定在助眠药物制备中的应用 |
WO2022195173A1 (fr) | 2021-03-19 | 2022-09-22 | Orion Corporation | Formulations de tasipimidine et leur utilisation |
WO2024023261A1 (fr) | 2022-07-27 | 2024-02-01 | Universität Zürich | Dexmédétomidine pour le traitement de troubles du sommeil |
US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
CN117771220B (zh) * | 2024-02-28 | 2024-05-28 | 山东第二医科大学 | 一种右美托咪定中药多糖口溶膜剂及其制备方法和应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7632517B2 (en) * | 1997-10-01 | 2009-12-15 | Novadel Pharma Inc. | Buccal, polar and non-polar spray containing zolpidem |
US20030022926A1 (en) * | 2001-05-07 | 2003-01-30 | Lavand'homme Patricia | Method for treating neuropathic pain and pharmaceutical preparation therefor |
US20050222270A1 (en) * | 2004-02-26 | 2005-10-06 | Olney John W | Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis |
JP2008514612A (ja) * | 2004-09-23 | 2008-05-08 | ミシャロウ、アレクサンダー | 対抗適応を誘発することにより神経伝達物質系を調節する方法 |
US20090076156A1 (en) * | 2005-07-18 | 2009-03-19 | Masud Husain | Use of a noradrenergic agonist, e.g. guanfacine, for the treatment of cognitive disorders |
EP1986642B1 (fr) * | 2006-02-13 | 2013-11-13 | Orient Pharma (Samoa) Co, Ltd | Combinaison d'un agoniste du récepteur alpha 2 (clonidine) et d'un agent anti-muscarinique (oxybutynine) pour le traitement de la sialorrhée |
EP2112923A1 (fr) * | 2007-01-22 | 2009-11-04 | Targacept Inc. | Administration intranasale, buccale ou sublinguale d'analogues de métanicotine |
WO2008141264A1 (fr) * | 2007-05-10 | 2008-11-20 | Novadel Pharma Inc. | Compositions et procédés anti-insomnie |
PE20091084A1 (es) * | 2007-12-07 | 2009-07-23 | Schering Plough Healthcare | Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal |
EP2370136A4 (fr) * | 2008-12-01 | 2015-12-30 | Map Pharmaceuticals Inc | Procédés et dispositif d'administration par inhalation |
KR101859486B1 (ko) * | 2009-05-15 | 2018-06-28 | 레크로파마, 인코포레이티드 | 설하용 덱스메데토미딘 조성물과 그의 사용 방법 |
JP2013516482A (ja) * | 2010-01-08 | 2013-05-13 | レクロ・ファーマ,インコーポレーテッド | 局所経皮用デクスメデトミジン組成物およびそれらの使用方法 |
US8241661B1 (en) * | 2011-06-24 | 2012-08-14 | Fuisz Richard C | Biocompatible film with variable cross-sectional properties |
WO2013061161A2 (fr) * | 2011-10-28 | 2013-05-02 | Green Bcn Consulting Services Sl | Nouvelles polythérapies destinées au traitement de troubles neurologiques |
AU2012352528B9 (en) * | 2011-12-11 | 2017-11-02 | Baudax Bio, Inc. | Intranasal dexmedetomidine compositions and methods of use thereof |
TWI709417B (zh) * | 2013-10-07 | 2020-11-11 | 美商帝國製藥美國股份有限公司 | 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物 |
-
2015
- 2015-10-14 MA MA041689A patent/MA41689A/fr unknown
- 2015-10-15 EP EP15850725.1A patent/EP3206685B1/fr active Active
- 2015-10-15 JP JP2017520539A patent/JP2017534613A/ja active Pending
- 2015-10-15 US US15/519,463 patent/US20170239221A1/en not_active Abandoned
- 2015-10-15 WO PCT/US2015/055828 patent/WO2016061413A1/fr active Application Filing
-
2021
- 2021-02-22 JP JP2021025810A patent/JP2021080276A/ja active Pending
-
2023
- 2023-03-07 JP JP2023034704A patent/JP2023076465A/ja active Pending
- 2023-09-05 US US18/242,236 patent/US20230414572A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3206685A4 (fr) | 2018-06-20 |
US20170239221A1 (en) | 2017-08-24 |
US20230414572A1 (en) | 2023-12-28 |
EP3206685B1 (fr) | 2024-05-08 |
EP3206685A1 (fr) | 2017-08-23 |
JP2023076465A (ja) | 2023-06-01 |
JP2017534613A (ja) | 2017-11-24 |
JP2021080276A (ja) | 2021-05-27 |
WO2016061413A1 (fr) | 2016-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA41689A (fr) | Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine | |
MA45192A (fr) | Traitement d'association | |
MA51815A (fr) | Méthodes de traitement ou de prévention de migraines avec anticorps contra le receptor de cgrp | |
IL246833A0 (en) | New salts and their pharmaceutical preparations for the treatment of inflammatory disorders | |
MA39753A (fr) | Inhibiteurs de diacylglycérol acyltransférase pour le traitement de troubles métaboliques ou analogues | |
FI20155065A (fi) | Monikäyttölaite eläimen hoitoon | |
MA44875A (fr) | Compositions pour le traitement de troubles acido-basiques | |
MA39722A (fr) | Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11 | |
HK1256721A1 (zh) | 用於治療眼部病症的化合物和組合物 | |
FR3011467B1 (fr) | Composes et compositions comprenant de tels composes pour la prevention ou le traitement des dyslipidemies | |
MA52252A (fr) | Formulation de poudre nasale pour le traitement de l'hypoglycémie | |
IT201600121601A1 (it) | Composizione orale per il trattamento del reflusso gastroesofageo e del reflusso laringo-faringeo | |
GB201401086D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
MA45226A (fr) | Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate | |
MA45552A (fr) | Compositions destinées au traitement de l'amylose | |
FR3022139B1 (fr) | Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee | |
FR3015285B1 (fr) | Formulation pour le traitement des cheveux | |
IT201600121617A1 (it) | Composizione per il trattamento del reflusso gastroesofageo | |
FR3044227B1 (fr) | Derives aminophosphiniques pour la prevention et le traitement des douleurs oculaires | |
DE112015002229A5 (de) | Formulierungen zur Behandlung von Hyperthyreose | |
IL248935A0 (en) | Diagnostic testing and treatment/prevention of Alzheimer's disease | |
FR3000895B1 (fr) | Utilisation d'antidotes d'inhibiteurs de la coagulation indiques dans la prevention ou le traitement de pathologies thromboemboliques | |
PL3137097T3 (pl) | Leczenie i profilaktyka choroby Alzheimera (AD) | |
FR3017536B1 (fr) | Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase | |
HUE037501T2 (hu) | Alzheimer-kór (AD) kezelése és megelõzése |